GLP-1 Drugs and Next-Gen Metabolic Therapies Show Promise for Kidney Disease | Research

The takeaway

A comprehensive review examines how GLP-1 receptor agonists and emerging metabolic hormone therapies may slow chronic kidney disease progression within the cardiovascular-kidney-metabolic syndrome framework.

CKM syndrome framework
GLP-1 RAs positioned as multi-organ protective agents beyond glucose control

What the researchers found

GLP-1 RAs and emerging metabolic hormone therapies show significant potential for slowing CKD progression, particularly within the CKM syndrome framework.

Why it matters

CKD affects hundreds of millions worldwide and is closely linked to diabetes and obesity. Repurposing metabolic therapies for kidney protection could transform CKD management.

How the study worked

Narrative review synthesizing clinical trial data, mechanistic studies, and guideline recommendations for incretin-based CKD therapies.

What this study cannot tell us

Narrative review — selective in literature coverage; dedicated CKD outcome trials for newer agents are still ongoing.

How to read the evidence

Narrative review in a top nephrology journal — authoritative synthesis but not a systematic review with formal evidence grading.

When this study was published

Published 2026 in Nature Reviews Nephrology. Reflects the latest clinical trial landscape.

The bigger picture

The reclassification of CKD management from isolated nephrology care to integrated metabolic disease treatment represents a paradigm shift with GLP-1 RAs at the forefront.

Questions still open

Which next-generation metabolic hormone therapies will show the strongest renal benefits?
How should GLP-1 RAs be positioned relative to SGLT2 inhibitors for CKD management?

Common questions

Can GLP-1 drugs help protect the kidneys?

Growing evidence suggests GLP-1 receptor agonists can slow kidney disease progression, particularly in patients with diabetes and obesity, through mechanisms beyond blood sugar control.

What is CKM syndrome?

Cardiovascular-kidney-metabolic syndrome recognizes that heart disease, kidney disease, diabetes, and obesity are interconnected conditions sharing common pathways that should be managed together.

Read the original research

GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease.

Nature reviews. Nephrology

View on PubMed ↗Publisher’s paper ↗

Citation

Alicic, Radica Z; Neumiller, Joshua J; Tuttle, Katherine R. (2026). GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease.. Nature reviews. Nephrology. https://doi.org/10.1038/s41581-025-01036-y